Skip to main content
SpringerLink
Log in

Treatment of Neuroblastoma with a Novel Delayed Intensification Chemotherapy

  • Original Article
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Objectives

To test the feasibility of adding a novel delayed intensification chemotherapy to a dose-intensive induction regimen chemotherapy for high-risk neuroblastoma.

Methods

Patients enrolled in this study received chemotherapy in accordance with the design of the NB97 trial. At the end of the therapy, patients received three cycles of delayed intensification chemotherapy. The delayed intensification chemotherapy consists of two A1 and one A2 cycle. The A1 cycle consists of 1.5 mg/m2 of vincristine on day 1, 1.2 g/m2 of cyclophosphamide on day 2, 100 mg/m2 of cisplatin on day 3, and 160 mg/m2 of etoposide on day 4. The A2 cycle is similar to the A1 cycle, however the only difference is that on day 4, 30 mg/m2 of doxorubicin is substituted for etoposide.

Results

Between 2007 to 2011, a total of thirty-six patients were enrolled, sixteen patients were long term event-free survivors. Three patients were alive with tumor whilst fifteen patients died. The 3-year Event free survival (EFS) and Overall survival (OS) were 44.4% (95%CI, 27.4 to 61.5%) and 50% (95%CI, 32.8 to 67.2%) respectively.

Conclusions

A high rate of survival among patients with high-risk neuroblastoma was achieved with delayed intensification chemotherapy without the occurrence of a second malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a children’s oncology group study. J Clin Oncol. 2011;29:4351–7.

  2. Seeger RC. Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol. 2011;21:229–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Calafiore L, Amoroso L, Della Casa Alberighi O, et al. Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma. Ann Oncol. 2013;24:1406–13.

  4. Valteau-Couanet D, Le Deley MC, Bergeron C, et al. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. Pediatr Blood Cancer. 2014;61:977–81.

    Article  CAS  PubMed  Google Scholar 

  5. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:649–58.

  6. Cohn SL, Pearson AD, London WB, et al; INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27:289–97.

  7. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165–73.

  8. Mueller S, Matthay KK. Neuroblastoma: biology and staging. Curr Oncol Rep. 2009;11:431–8.

    Article  PubMed  Google Scholar 

  9. Ambros IM, Benard J, Boavida M, et al. Quality assessment of genetic markers used for therapy stratification. J Clin Oncol. 2003;21:2077–84.

  10. Berthold F, Hero B, Kremens B, et al. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett. 2003;197:11–7.

  11. Schmidt M, Simon T, Hero B, Schicha H, Berthold F. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer. 2008;44:1552–8.

    Article  PubMed  Google Scholar 

  12. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatr Blood Cancer. 2011;56:578–83.

    Article  PubMed  Google Scholar 

  13. Brodeur G, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–77.

    Article  CAS  PubMed  Google Scholar 

  14. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.

  15. Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res. 2011;2:109–12.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Ladenstein R, Weixler S, Baykan B, et al. Ch14.18 antibody produced in CHO cells in relapsed or refractory stage 4 neuroblastoma patients: a SIOPEN phase 1 study. MAbs. 2013;5:801–9.

  17. Campigotto F, Weller E. Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials. J Clin Oncol. 2014;32:3068–74.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Oncology, The First Hospital of Jilin University, Changchun, Jilin, China

    Yu-tong Zhang, Jian Chang & Xiao-dan Zhong

  2. Department of Obstetrics and Gynecology, The First Hospital of Jilin University, Changchun, Jilin, China

    Hong-mei Xu

  3. Department of Pediatric Respiratory, The First Hospital of Jilin University, Changchun, Jilin, China

    Ya-nan Li

  4. Department of Oncology, The First Hospital of Jilin University, Changchun, 130021, Jilin, China

    Zi-ling Liu

Authors
  1. Yu-tong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jian Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong-mei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ya-nan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiao-dan Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zi-ling Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Y-TZ: Conceptualized and designed the study, drafted the initial manuscript, and approved the final manuscript as submitted; JC, H-mX and Z-lL: Carried out the initial analyses, reviewed and revised the manuscript, and approved the final manuscript as submitted; Y-nL and X-dZ: Designed the data collection instruments, and coordinated and supervised data collection at two of the four sites, critically reviewed the manuscript, and approved the final manuscript as submitted. Z-lL will act as guarantor for this paper.

Corresponding author

Correspondence to Zi-ling Liu.

Ethics declarations

Approved by Medical Ethics Committee of the First Hospital of Jilin University, Changchun, China. No: 2008–002.

Conflict of Interest

None.

Electronic supplementary material

ESM 1

(XLSX 27.0 kb)

ESM 2

(XLS 8.46 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Yt., Chang, J., Xu, Hm. et al. Treatment of Neuroblastoma with a Novel Delayed Intensification Chemotherapy. Indian J Pediatr 86, 126–131 (2019). https://doi.org/10.1007/s12098-018-2737-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-018-2737-6

Keywords

Search

Navigation